^
    1year
    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=177, Recruiting, Jazz Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • JZP898
    1year
    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=177, Not yet recruiting, Jazz Pharmaceuticals
    New P1 trial • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • JZP898
    over1year
    WTX-613, (JZP898) a selectively activated IFNα INDUKINE™ molecule, reprograms the tumor microenvironment and generates robust anti-tumor immunity as a monotherapy and in combination with checkpoint inhibitors (AACR 2023)
    Finally, the combination of mWTX-613 treatment with various checkpoint inhibitor molecules resulted in improved anti-tumor efficacy in syngeneic models. Together, these data support the advancement of this innovative IFNα therapy into clinical testing.
    Combination therapy • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • IFNA1 (Interferon Alpha 1)
    |
    MHC-II expression
    |
    JZP898
    3years
    Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates (ASH 2021)
    The WTX-330 INDUKINE™ molecule, a wild-type IL-12 pro-drug, contains a half-life extension (HLE) domain to support infrequent dosing and a high affinity anti-IL-12 neutralizing antibody domain to maintain the molecule in its inactive state in the periphery. Similar studies for WTX-613 are on-going. Preclinical data obtained so far for both programs support the continued development and future evaluation of these innovative and differentiated therapies in hematologic malignancies, both as monotherapies and in multiple combinations with standard of care.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IFNA1 (Interferon Alpha 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    JZP898 • WTX-330
    3years
    WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models (SITC 2021)
    Specifically, the WTX-613 surrogate was better than native IFNα1 in inducing CD8+, NK, and DC cells. Conclusions Preclinical data obtained so far support the continued development of this innovative and differentiated engineered IFNα therapy and progression into clinical trials.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IFNA1 (Interferon Alpha 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    JZP898